Skip to content
value.today
Vaccinex, Inc. logo

Vaccinex, Inc.

VCNX
$9 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$1 M
For year ending December-2024
Net income
$-19 M
-3105.0% margin
SEC filing
Employees
23
As of December 31, 2024
SEC filing

Vaccinex, Inc. in brief

Vaccinex, Inc. is a listed company in the Biotechnology industry, based in Rochester, New York, USA. Its last known market value was $9 M (January 2024); there is no current figure. In the year to December 2024 it had sales of $1 M and a net loss of $19 M. It employs about 23 people. Its shares trade under the symbol VCNX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Vaccinex, Inc.

We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. We believe we are the leader in the field of semaphorin 4D, or SEMA4D, biology and that we are the only company targeting SEMA4D as a potential treatment for neurodegenerative diseases, cancer, and autoimmune disorders. SEMA4D is an extracellular signaling molecule that regulates the activity of immune and inflammatory cells at sites of injury, cancer, or infection. We have used our SEMA4D antibody platform and our extensive knowledge of SEMA4D biology to develop our lead product candidate, pepinemab, an antibody that we believe utilizes novel mechanisms of action. We are focused on developing pepinemab for the treatment of Alzheimer’s disease, or AD and as our resources allow, also developing pepinemab for head and neck cancer, and pancreatic cancer. Additionally, third party investigators have studied pepinemab in clinical trials in breast cancer, as well as in “window of opportunity” studies in other indications, including melanoma. We have developed multiple proprietary platform technologies and product candidates to address serious diseases or conditions that have a substantial impact on day-to-day functioning and for which treatment is not addressed adequately by available therapies.

From the company's annual report filed with the US SEC: read the report

Vaccinex, Inc. timeline

3 events, 2002–2021
  1. 2002
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2018
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 10 August 2018; shares registered for exchange trading on 8 August 2018.
  5. 2021
  6. 💰
    Record revenue of $1 million
    FY2021, the highest of the 7 years on record.

Events of Vaccinex, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$21 M$41 M$62 M$82 M20202021202220232024

World rank over time

▼ down 11,212 places since 2020
2020-01-01: #20053#20,05320202021-01-01: #20948#20,94820212022-01-07: #28706#28,70620222022-12-25: #27078#27,07820222023-07-30: #29730#29,73020232024-01-05: #31265#31,2652024

Rank in USA: #3,877 (Jan 2020) · #4,106 (Jan 2021) · #5,112 (Jan 2022) · #5,023 (Dec 2022) · #5,223 (Jul 2023) · #4,534 (Jan 2024)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-3105.0%
Operating margin
-3123.3%
Return on equity
—
Liabilities / assets
195.4%
Net debt
$-1M
Revenue growth
+5.3%
R&D / revenue
2090.0%
Revenue per employee
$26 K
Profit per employee
$-810 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue —, net income $-19M—FY17Fiscal year ending Dec 2018: revenue $1M, net income $-30M$1MFY18Fiscal year ending Dec 2019: revenue $1M, net income $-32M$1MFY19Fiscal year ending Dec 2020: revenue $1M, net income $-29M$1MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-22M$1MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-20M$0MFY22Fiscal year ending Dec 2023: revenue $1M, net income $-20M$1MFY23Fiscal year ending Dec 2024: revenue $1M, net income $-19M$1MFY24
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2024$1M+5.3%$-19M$-19M-3105.0%
Dec 2023$1M+103.6%$-23M$-20M-3552.6%
Dec 2022$0M-68.9%$-20M$-20M-7078.6%
Dec 2021$1M+45.2%$-22M$-22M-2486.7%
Dec 2020$1M+19.2%$-28M$-29M-4653.2%
Dec 2019$1M-27.8%$-32M$-32M-6126.9%
Dec 2018$1M—$-27M$-30M-4100.0%
Dec 2017——$-21M$-19M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2024$-16M$0M$-16M$-8.88—
Dec 2023$-21M$0M$-21M$-43.68—
Dec 2022$-19M$0M$-19M$-98.05—
Dec 2021$-25M$0M$-25M$-0.78—
Dec 2020$-29M$0M$-29M$-1.54—
Dec 2019$-31M$0M$-31M$-2.47—
Dec 2018$-25M$0M$-26M$-5.65—
Dec 2017$-21M$0M$-21M$-19.90—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$1M
Net income, trailing 12 months
$-19M
RevenueNet income
Three months to Mar 2023: revenue $1M, net income $-5M$1MMar ’23Three months to Jun 2023: revenue —, net income $-7M—Jun ’23Three months to Sep 2023: revenue $0M, net income $-5M$0MSep ’23Three months to Dec 2023 (from the annual report): revenue —, net income $-3M—Dec ’23Three months to Mar 2024: revenue $0M, net income $-4M$0MMar ’24Three months to Jun 2024: revenue $0M, net income $-6M$0MJun ’24Three months to Sep 2024: revenue $0M, net income $-6M$0MSep ’24Three months to Dec 2024 (from the annual report): revenue $0M, net income $-3M$0MDec ’24

Latest quarter to Dec 2024: revenue $0M, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Dec 2024.

SEC filings

Official filings of Vaccinex, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-19 M
Net income
$-19 M

For year ending December-2024 · source: SEC filing

Balance sheet

Total assets
$3 M
Total liabilities
$5 M
Total equity
$-2 M

As of December-2024

Insider trading at Vaccinex, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
9
since
$1.2 M-$3 K$0Dec 2023: bought $0 (0 trades), sold $3 K (2 trades)Dec 23Apr 2024: bought $1 K (1 trades), sold $0 (0 trades)AprMay 2024: bought $9 K (2 trades), sold $0 (0 trades)MayJul 2024: bought $1.2 M (3 trades), sold $0 (0 trades)JulAug 2024: bought $86 K (4 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Vaccinex, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Albert FriedbergDirector, 10% ownerGrant or awardindirect+30,756$3.250$100 K1.05 MForm 4
filed Maurice ZaudererPresident and CEO, Director, 10% ownerGrant or awardindirect+46,153$3.250$150 K297,941Form 4
filed Maurice ZaudererPresident and CEO, Director, 10% ownerOption exerciseindirect+38,610$5.640$218 K176,748Form 4
filed Albert FriedbergDirector, 10% ownerOption exerciseindirect+214,286$5.640$1.2 M994,910Form 4
filed Albert FriedbergDirector, 10% ownerOption exerciseindirect+25,723$5.640$145 K1.02 MForm 4
filed Maurice ZaudererPresident and CEO, Director, 10% ownerOption exerciseindirect+29,557$5.640$167 K206,305Form 4
filed Maurice ZaudererPresident and CEO, Director, 10% ownerOption exerciseindirect+9,768$5.640$55 K216,073Form 4
filed Maurice ZaudererPresident and CEO, Director, 10% ownerOption exerciseindirect+35,715$5.640$201 K251,788Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Vaccinex, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
2,106
3.18 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-7.14 reverse split ; 1-for-6.67 reverse split

Trading halts

  • 2024-12-17 14:35 UTC, code LUDP, resumed 14:40 UTC

Fails to deliver

  • : 27 shares at $0.83
  • : 999 shares at $1.15
  • : 1 shares at $0.70
  • : 1 shares at $0.70
  • : 100 shares at $0.76

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Vaccinex, Inc. scorecard#

Passes 3 of the 9 checks that could be worked out: strongest in growth (2 of 3), weakest in financial health (1 of 3). Fiscal year 2024.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth2 of 3
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-8.88 vs -43.68Diluted EPS -8.88 in fiscal 2024 against -43.68 the year before (report's currency).
    • ✓Net income higher than five years earlier-$19 M-$19 M in fiscal 2024 against -$32 M in 2019.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2024.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$19 MNet income -$19 M in fiscal 2024.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2024.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✗Short-term assets cover short-term liabilities0.5×Current ratio 0.50 at the end of fiscal 2024.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $1 M at the end of fiscal 2024.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2024.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year352.4%Diluted shares up 352.4% in fiscal 2024.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Vaccinex, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Vaccinex, Inc.: statements by fiscal year
PeriodTrendFY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017
Income statement
Revenue0.60.60.30.90.6r0.50.70.1
Cost of revenue————0.00.21.00.2
Research and development1317141722262217
General and administrative6.86.96.26.27.46.74.64.5
Total costs and expenses1923202329332821
Operating income−19−23−20−22−28−32−27−21
Interest expense and finance costs0.00.00.00.80.5—0.41.4
Other non-operating income (expense)0.00.90.10.0−0.00.20.2−0.0
Income before tax−19−20−20−22−29−32−30−19
Income tax00000000
Net income including minority interests−19−20−20−22−29−32−30−19
Minority interests' share of net income———0000−0.0
Net income attributable to shareholders−19−20−20−22−29−32−30−19
Earnings per share, basic-8.88-43.68-98.05r-0.78-1.54-2.47-5.65-19.90
Earnings per share, diluted-8.88-43.68-98.05r-0.78-1.54-2.47-5.65-19.90
Shares, weighted average (basic)2.10.50.2r29————
Shares, weighted average (diluted)2.10.50.2r2919135.21.1
Balance sheet
Cash and cash equivalents1.11.56.48.6112.85.64.2
Short-term investments—————014—
Receivables0.81.00.2—0.20.90.60.1
Other current assets0.60.90.90.80.50.31.10.7
Current assets2.53.37.59.4114.0215.0
Property, plant and equipment0.10.10.20.30.40.60.60.6
Right-of-use (leased) assets00.10.30.1————
Total assets2.63.68.09.8124.6225.6
Accounts payable4.02.01.51.13.23.22.31.9
Debt due within a year0.00.10.10.1————
Current liabilities5.15.92.52.3136.96.74.2
Long-term debt00.00.10.21.1———
Lease liabilities (non-current)——0.1—————
Total liabilities5.15.92.82.4146.96.77.3
Retained earnings−359−340−320−300−277−249−217−187
Shareholders' equity———7.4−27−26−8.6−125
Minority interests————24242412
Total equity−2.5−2.35.27.4−2.6−2.315−113
Total liabilities and equity2.63.68.09.8124.6225.6
Shares outstanding2.70.90.2r312215111.1
Cash-flow statement
Depreciation and amortization—————0.20.20.2
Share-based compensation0.30.50.50.50.70.40.20.3
Cash from operating activities−16−21r−19−25−29−31−25−21
Capital expenditure−0.0−0.1−0.1−0.0−0.3−0.1−0.2−0.1
Cash from investing activities−0.0−0.1−0.1−0.0−0.314−14−0.1
Debt issued————1.1———
Debt repaid−0.1−0.1−0.1−0.0————
Shares issued—1.33.63317———
Cash from financing activities1617r172337144124
Change in cash−0.4−4.9−2.2−2.07.8−2.81.42.5
Report10-K10-K10-K/A10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Vaccinex, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 5 · Directors and officers 3 · Material agreement 6 · Unregistered share sale 5 · Shareholder rights changed 2 · Bylaws or fiscal year changed 3 · Shareholder vote 2

Vaccinex, Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Delisting notice8-K
Delisting notice8-K
Material agreementUnregistered share sale8-K
Delisting notice8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Shareholder vote8-K
Delisting notice8-K
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Directors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Delisting notice8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Shareholder rights changedBylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Mar 19, 2025

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Vaccinex, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2024$2 MPrivate placement after listingUnder $2 million1equity, optionsSEC
Mar 2024$1 MPrivate placement after listingUnder $2 million3equity, optionsSEC
Sep 2020$2 MPrivate placement after listing$2 to $10 million1equitySEC
Jul 2020$4 MPrivate placement after listing$2 to $10 million1equitySEC
Jan 2020$7 MPrivate placement after listing$2 to $10 million5equitySEC
Jul 2019$14 MPrivate placement after listing$10 to $50 million5equitySEC
May 2017$6 MNo. 1$2 to $10 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Vaccinex, Inc. compares in Biotechnology

  • Revenue$1 M · higher than 22% of 647
  • Revenue growth5.3% · higher than 50% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Vaccinex, Inc.🇺🇸$9 M——+5.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2024
Balance sheet:
As of December-2024
Employees:
As of December 31, 2024
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Vaccinex, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Vaccinex, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Vaccinex, Inc.? Suggest a correction